Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift?
Koffas A Mak L Y Gill U S et al
Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift? , U.K. & Hong Kong - 12p. - Viruses Vol. 4 (5) .
To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection.
Related terms Hep B, HBV.
Available in: English
Treatment & research: Medical treatment
Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift? , U.K. & Hong Kong - 12p. - Viruses Vol. 4 (5) .
To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection.
Related terms Hep B, HBV.
Available in: English
Treatment & research: Medical treatment
